Ireland
--:--IST
Starting soon Phase 2

Alberta Cancer Exercise Dose in Colorectal Cancer

NCT07913906 · tracked via the Priya Life Science Canada tracker
Phase
Phase 2
Started
2027-01
Last updated
2026-11-06

Condition(s) studied

CancerColorectal Cancer

Investigational drug(s) / intervention(s)

Group Exercise Classes - Arm 1Group Exercise Classes - Arm 2

Group Exercise Classes - Arm 1: Interventional arm 1 complete the supervised 60-min exercise classes for 12 weeks at low-to-moderate intensity, progressing individually (warm-up, aerobic intervals, multi-joint resistance, balance/flexibility cool-down), once-weekly. Sessions are delivered in-person by a CEP at the ACCCC Stride Centre. Attendance, RPE, and any modifications/adverse events are logged each session. In addition to exercise, 5 behaviour components will be covered throughout the program using an "Exercise and Educate" model, to support behaviour change. The trained instructor will build a positive motivational climate utilizing training in health coaching and motivational interviewing.

Group Exercise Classes - Arm 2: Interventional arm 2 complete the supervised 60-min exercise classes for 12 weeks at low-to-moderate intensity, progressing individually (warm-up, aerobic intervals, multi-joint resistance, balance/flexibility cool-down), twice-weekly. Sessions are delivered in-person by a CEP at the ACCCC Stride Centre. Attendance, RPE, and any modifications/adverse events are logged each session. In addition to exercise, 5 behaviour components will be covered throughout the program using an "Exercise and Educate" model, to support behaviour change. The trained instructor will build a positive motivational climate utilizing training in health coaching and motivational interviewing.

Study summary

The purpose of this pilot randomized, wait-list controlled study is to evaluate the effects of exercise dose in terms of frequency (1 vs. 2 days per week) in individuals on systemic treatment for colorectal cancer. The impact on the individual (physical function, quality of life, fatigue and other patient reported outcomes) as well as on health care utilization (cost to deliver, cost to individuals, savings and impact to the health care system) will be evaluated. In addition, assessments of immunological markers to better understand the biological impact of exercise dose on immunological markers will be explored.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults (≥18) * Have a primary biopsy-proven diagnosis of colon or rectal adenocarcinoma and undergoing adjuvant systemic treatment * Cleared for exercise (PAR-Q+) * Able to attend scheduled sessions * Able to provide informed written consent in English. * Not meeting current aerobic exercise guidelines (i.e. performing \< 90 minutes of moderate to vigorous physical activity per week in the past month) Exclusion Criteria: * Participants who have completed adjuvant treatment for CRC * Unstable cardiopulmonary disease * Uncontrolled hypertension * Active infection * Recent autoimmune flare * Contraindication to needles/venipuncture * Grade 2 or higher diarrhea secondary to systemic treatment

Primary outcome measure(s)

  • Proportion of patients in the once per week and twice per week group that achieve an increase of ≥10 MET-h/wk of total physical activity level at 12 weeks. — Single time point: 12 weeks
    To assess the dose-response effect of exercise frequency (once versus twice weekly) over a 12-week period on clinically meaningful improvements in physical activity level (≥10 MET-h/wk increase over baseline) in patients with early-stage CRC receiving systemic treatment, with the goal of identifying the minimal effective intervention frequency

Trial sites (1)

FacilityCityRegionStatus
Arthur J.E. Child Comprehensive Cancer Centre - Gastrointestinal tumour group outpatient clinics Calgary Alberta
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07913906 on ClinicalTrials.gov ↗ ← All trials in Canada